Gillette P N, Manning J M, Cerami A
Proc Natl Acad Sci U S A. 1971 Nov;68(11):2791-3. doi: 10.1073/pnas.68.11.2791.
Cyanate reacts with the amino-terminal valine residues of hemoglobin S and prevents the sickling in vitro of 50-80% of the erythrocytes from patients with sickle-cell disease. The purpose of the studies reported here was to determine whether this anti-sickling effect would increase the survival of cyanate-treated cells that were returned to the patient. In seven subjects with sickle-cell disease, the mean 50% survival of (51)Cr-labeled sickle erythrocytes was increased from 9.9 to 20.7 days (normal 25-35 days) after treatment of the cells in vitro with sodium cyanate. These results provide evidence that the antisickling effect of cyanate observed in vitro is retained in vivo, and strengthen the rationale for further investigation of cyanate as a possible therapeutic agent in sickle-cell disease.
氰酸盐与血红蛋白S的氨基末端缬氨酸残基发生反应，可在体外防止50%至80%的镰状细胞病患者红细胞发生镰变。本文报道的研究目的是确定这种抗镰变效应是否会提高返回患者体内的经氰酸盐处理细胞的存活率。在7名镰状细胞病患者中，用氰酸钠对细胞进行体外处理后，（51）铬标记的镰状红细胞的平均50%存活率从9.9天提高到了20.7天（正常为25至35天）。这些结果证明，在体外观察到的氰酸盐抗镰变效应在体内也能保持，从而为进一步研究氰酸盐作为镰状细胞病可能的治疗药物提供了理论依据。
